Given that the inversed expression of c-Myc and TXNIP during either CML transformation or imatinib treatment (Fig. 1A, C, E), we suppose c-Myc is involved in BCR-ABL suppression of TXNIP transactivation in CML cells. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.